IP Library Granted Patent US 8,128,951
Granted Patent B2
US 8,128,951 · App. 12/712,134 · Granted Mar 6, 2012

Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,128,951
App. No.
12/712,134
Granted
Mar 6, 2012
Kind
B2
Abstract

A method and device for local delivery of water-soluble or water-insoluble therapeutic agents to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which is complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

Claims (30)

1. A catheter assembly for insertion into the vasculature comprising:

an expandable structure having an outer surface;

a non-durable coating disposed on the outer surface of the expandable structure, wherein the non-durable coating comprises a polymer matrix which is complexed with iodine; and

a substantially water-insoluble therapeutic agent dispersed in the matrix which is complexed with the iodine.

2. The catheter assembly of claim 1 , wherein the polymer matrix is a continuous aggregate polymer matrix which is uniformly dissolvable and removable from the outer surface of the expandable structure in an aqueous solvent, and at least partially dissolvable in a non-aqueous solvent.

3. The catheter assembly of claim 2 , wherein the continuous aggregate polymer matrix comprises an amphiphilic polymer or co-polymer which is fully dissolvable in a solution having a range of 100% to 80% non-aqueous solvent, and 0% to 20% aqueous solvent.

4. The catheter assembly of claim 1 , wherein said non-durable coating is dissolvable in bovine serum such that 50%, by volume, of said non-durable coating is removed within 180 seconds of soaking in bovine serum at 37° C.

5. The catheter assembly of claim 4 , wherein said non-durable coating is dissolvable in bovine serum such that 90%, by volume, of said non-durable coating is removed within 300 seconds of soaking in bovine serum at 37° C.

6. The catheter assembly of claim 1 , wherein said iodine is complexed with polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP) or hydroxypropyl cellulose (HPC).

7. The catheter assembly of claim 1 , wherein said water-insoluble therapeutic agent is paclitaxel.

8. The catheter assembly of claim 2 , wherein the continuous aggregate polymer matrix is uniformly dissolvable and removable from the outer surface in both aqueous solvent and non-aqueous solvent.

9. A catheter assembly of claim 1 , wherein said iodine is present in said coating at a weight ratio of 1-30% of said coating dry weight.

10. The catheter assembly of claim 1 , wherein said iodine is complexed with methyl cellulose, hydroxypropyl methylcellulose, or a co-polymer of N-vinylpyrrolidone with a reactive double bond containing monomer.

11. The catheter assembly of claim 10 , wherein the reactive double bond containing monomer is selected from the group consisting of styrene, acrylic acid, vinyl acetate and vinyl caprolactam.

12. The catheter assembly of claim 1 , wherein the substantially water-insoluble therapeutic agent is dispersed throughout the polymer matrix which is complexed with the iodine.

13. A catheter assembly for insertion into the vasculature comprising:

an expandable structure having an outer surface;

a non-durable coating disposed on the outer surface of the expandable structure, wherein the non-durable coating comprises a polymer matrix; and

a substantially water-insoluble therapeutic agent and non-covalently bound iodine dispersed throughout the polymer matrix.

14. The catheter assembly of claim 13 , wherein the polymer matrix is a continuous aggregate polymer matrix which is dissolvable and removable from the outer surface of the expandable structure in an aqueous solvent, and at least partially dissolvable in a non-aqueous solvent.

15. The catheter assembly of claim 14 , wherein the continuous aggregate polymer matrix comprises an amphiphilic polymer or co-polymer which is fully dissolvable in a solution having a range of 100% to 80% non-aqueous solvent, and 0% to 20% aqueous solvent.

16. The catheter assembly of claim 13 , wherein the polymer matrix comprises a polymer selected from the group consisting of polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP) and hydroxypropyl cellulose (HPC).

17. The catheter assembly of claim 13 , wherein the water-insoluble therapeutic agent is paclitaxel.

18. A catheter assembly of claim 13 , wherein the iodine is present in the coating at a weight ratio of 1-30% of said coating dry weight.

19. The catheter assembly of claim 13 , wherein the polymer matrix comprises a polymer selected from the group consisting of methyl cellulose and hydroxypropyl methylcellulose, or a co-polymer of N-vinylpyrrolidone with a reactive double bond containing monomer.

20. The catheter assembly of claim 19 , wherein the reactive double bond containing monomer is selected from the group consisting of styrene, acrylic acid, vinyl acetate and vinyl caprolactam.

21. The catheter assembly of claim 1 , wherein the polymer matrix comprises polyethylene glycol (PEG).

22. The catheter assembly of claim 21 , wherein the PEG has a molecular weight of 1.5 KD to 50 KD.

23. The catheter assembly of claim 13 , wherein the polymer matrix comprises polyethylene glycol (PEG).

24. The catheter assembly of claim 23 , wherein the PEG has a molecular weight of 1.5 KD to 50 KD.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: THE SPECTRANETICS CORPORATION
Reel/Frame 037268/0793 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0425 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0506 →
SECURITY INTEREST Recorded Jul 2, 2015
From: THE SPECTRANETICS CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 036055/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2015
From: COVIDIEN LP
To: THE SPECTRANETICS CORPORATION
Reel/Frame 035074/0106 →
MERGER Recorded Aug 9, 2013
From: CV INGENUITY LLC
To: COVIDIEN LP
Reel/Frame 030974/0870 →
CHANGE OF NAME Recorded Aug 9, 2013
From: CV INGENUITY CORP.
To: CV INGENUITY LLC
Reel/Frame 030994/0255 →
RELEASE OF SECURITY INTEREST Recorded Jun 5, 2012
From: VENTURE LENDING & LEASING V, INC.; VENTURE LENDING & LEASING VI, INC.
To: CV INGENUITY CORP.
Reel/Frame 028317/0349 →
NUNC PRO TUNC ASSIGNMENT Recorded May 9, 2011
From: CV INGENUITY
To: CV INGENUITY CORP.
Reel/Frame 026248/0130 →
SECURITY AGREEMENT Recorded Feb 9, 2011
From: CV INGENUITY CORP.
To: VENTURE LENDING & LEASING VI, INC.; VENTURE LENDING & LEASING V, INC.
Reel/Frame 025780/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2010
From: MICHAL, EUGENE T.; LERNER, DANIEL J.; POLLMAN, MATTHEW J.
To: CV INGENUITY
Reel/Frame 024241/0168 →